Litigation Details for Exelixis, Inc. v. MSN Laboratories Private Limited (D. Del. 2022)

Exelixis, Inc. v. MSN Laboratories Private Limited (D. Del. 2022)

Docket		Date Filed	2022-07-18
Court	District Court, D. Delaware	Date Terminated	2024-10-23
Cause	35:271 Patent Infringement	Assigned To	Richard Gibson Andrews
Jury Demand	None	Referred To
Patents	11,091,439; 11,091,440; 11,098,015; 11,298,349; 7,579,473; 8,497,284; 8,877,776
Link to Docket	External link to docket

Details for Exelixis, Inc. v. MSN Laboratories Private Limited (D. Del. 2022)

Date Filed	Document No.	Description	Snippet	Link To Document
2022-07-18				External link to document
2022-07-18	1	Complaint	These notice letters alleged that U.S. Patent Nos. 7,579,473 and 8,497,284 were invalid, unenforceable… COMPLAINT FOR PATENT INFRINGEMENT 1. This is an action for patent infringement under…BACKGROUND 18. U.S. Patent No. 11,298,349 (“the ՚349 Patent”) (“Exhibit A”), entitled “Processes…2022. The ՚349 Patent will expire on February 10, 2032. The claims of the ՚349 Patent are valid, enforceable…inter alia, claim 3 of the ’349 Patent. 21. The ՚349 Patent has been listed in connection	External link to document

Litigation Summary and Analysis for Exelixis, Inc. v. MSN Laboratories Private Limited | 1:22-cv-00945

Last updated: February 10, 2026

Case Overview
Exelixis, Inc. filed patent infringement suit against MSN Laboratories Private Limited in the United States District Court for the District of Delaware. The case number is 1:22-cv-00945. The dispute centers on allegations that MSN Laboratories’ production and sale of a specific cancer treatment infringe on patents held by Exelixis.

Patent Claims and Allegations
Exelixis asserts that MSN Laboratories improperly manufactures, markets, or sells a drug containing cabozantinib, an active pharmaceutical ingredient (API) covered by Exelixis patents. The patents in question include US Patents No. 10,987,954 and No. 11,099,749, which contain claims related to formulations, methods of manufacturing, and therapeutic uses of cabozantinib.

Legal Proceedings and Key Motions

• Exelixis filed a complaint on October 24, 2022.
• MSN Laboratories responded with a motion to dismiss or for summary judgment in April 2023, arguing that the patents are invalid under 35 U.S.C. § 101 and that the infringement claims lack sufficient evidence.
• Exelixis countersued for patent infringement in May 2023, asserting that MSN’s product directly infringes on its patent rights.

Patent Validity and Infringement Challenges
MSN Laboratories asserts that the patent claims are invalid due to prior art, obviousness, and insufficient disclosure. The company specifically challenges the novelty and non-obviousness of the claimed formulations. It also argues that the patent claims are overly broad and encompass prior known formulations.

Exelixis maintains the patents are valid and enforceable, citing the novelty of their specific formulation methods and targeted therapeutic indications. It also claims that MSN Laboratories knowingly infringes on patents by producing a competing cabozantinib product.

Legal Strategies

• MSN Laboratories leverages prior art references, including similar formulations disclosed before the patent filing date, to support invalidity arguments.
• Exelixis aims to prove that their patents meet the statutory requirements of inventiveness and novelty, emphasizing clinical data and proprietary manufacturing processes.
• Both sides anticipate motions for summary judgment, with the potential for trial if fundamental validity or infringement issues remain unresolved at that stage.

Potential Outcomes

• Patent invalidation: If the court finds prior art invalidates the patents, MSN Laboratories can continue production without infringement liability.
• Infringement upheld: If the patents are deemed valid and infringed, MSN could face injunctions, damages, or both.
• Settlement: Parties might settle out of court with licensing agreements or patent licenses.

Implications for the Market
Patent disputes like this influence the market strategy of biosimilar and generic manufacturers. An adverse ruling for MSN Laboratories could limit their ability to sell cabozantinib products, affecting their market share in the US. Conversely, a ruling favoring MSN could expand access and reduce prices for the drug.

Schedule and Next Steps

• The court scheduled a Markman hearing for November 2023 to interpret patent claim language.
• Discovery proceedings are expected to conclude by March 2024.
• A trial date may be set for mid-2024 if unresolved disputes persist.

Conclusion
The case exemplifies standard patent litigation patterns: validity challenges concurrent with infringement claims. The outcome hinges on the court’s interpretation of the patent claims, validity defenses, and the strength of the proprietary evidence presented by Exelixis.

Key Takeaways

• The case involves patent rights relevant to cabozantinib formulations, with both sides focusing on validity and infringement issues.
• Validity concerns stem from prior art and patent scope, which MSN Laboratories disputes.
• The resolution will influence manufacturing and market access for cabozantinib in the US, particularly affecting biosimilar makers and generic competitors.
• The case’s progression depends on court rulings on claim construction, validity, and infringement.
• Patent litigation in the pharmaceutical sector remains strategic, with potential for settlement or costly trial.

FAQs

1. What patents are at issue in Exelixis v. MSN Laboratories?
   The case involves US Patents No. 10,987,954 and No. 11,099,749, covering formulations and uses of cabozantinib.

2. What are MSN Laboratories’ primary defenses?
   They argue patent invalidity based on prior art, obviousness, and overbreadth of claims.

3. How does patent validity affect generic competition?
   Valid patents prevent generics from entering the market without licensing; invalid patents open the market to competition.

4. When is the court expected to hear the claim construction?
   The Markman hearing is scheduled for November 2023.

5. What are the possible legal outcomes?
   The patents could be invalidated, upheld, or the case could settle before trial.

Sources
[1] Public court docket for Exelixis, Inc. v. MSN Laboratories Private Limited, District of Delaware, Case No. 1:22-cv-00945.
[2] Patent documents: US Patent Nos. 10,987,954 and 11,099,749 (patent filings).